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We aimed to evaluate in a sample of outpatients with schizophrenia (SCZ) the
effectiveness of a cognitive remediation (CR) program (through the use of the Cogpack
software) [computer-assisted CR (CACR)] in addition to standard therapy on cognitive
outcomes as compared with that in a control active group (CAG) and to highlight a
possible effect on social cognition (SC), metacognition, symptomatology, and real-world
functioning. Of the 66 subjects enrolled, 33 were allocated to CACR and 33 to
the CAG. Twenty-three patients in the CACR group and 25 subjects in the CAG
completed at least 80% of the 48 prescribed CACR sessions, performed twice a
week, for a total of 24 weeks of treatment. A significant time × group interaction
was evident, suggesting that patients undergoing CACR intervention improved in
specific metacognitive sub-functions (understanding others’ mind and mastery), some
cognitive domains (verbal learning processing speed, visual learning, reasoning, and
problem solving) (h2 = 0.126), depressive symptoms, SC, awareness of symptoms,
and real-world functioning domains (community activities and interpersonal relationships)
more significantly than did patients undergoing CAG. The most noticeable differential
improvement between the two groups was detected in two metacognitive sub-functions
(understanding others’ mind andmastery), in verbal learning, in interpersonal relationship,
and in depressive symptomatology, achieving large effect sizes. These are encouraging
findings in support of the possible integration of CACR in rehabilitation practice in the
Italian mental health services.
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INTRODUCTION
Cognitive deficits represent one of schizophrenia’s (SCZ’s) core features since they affect patients’
functioning and are related to high levels of functional disability (1–4).
Moreover, cognitive impairment attenuates the potential benefit of rehabilitation programs,
such as supported employment and social skills training-, even when high-quality rehabilitation
is provided (5–7).
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Since cognitive deficits of patients with SCZ respond only
moderately to pharmacotherapy (8), cognitive remediation (CR)
techniques have received an increasing development in the last
15 years.
At the Cognitive Remediation Experts Workshop (Florence,
Italy, April 2010), CR has been defined as “a behavioral
training based intervention that aims to improve cognitive
processes (attention, memory, executive function, social
cognition, or metacognition) with the goal of durability and
generalization” (9).
It has proved to be an evidence-based approach for
ameliorating cognitive impairment in SCZ as confirmed in
different meta-analytic studies (9–12), which show significant
effect-size impact on cognition (0.45) and daily functioning
(0.36) (9, 10).
More specifically, Wykes et al. (9) found that cognitive
outcomes improve with both drill-and-practice and strategic
training; McGurk et al. (10) corroborated that drill or practice
training alone has a larger effect on memory and verbal learning,
when associated with strategic training. Lastly, Grynszpan et al.
(11) proved smaller effect sizes on verbal memory, working
memory, attention/vigilance, and speed of processing and a
significant medium effect size for social cognition (SC), while
general cognition provides positive results. Interestingly, it
appears that effects of CR programs are “non-specific”; targeted
cognitive domains did not reach higher improvement than those
that were not specifically targeted.
Computer-assisted CR (CACR) effects on cognition
have been widely analyzed in two recent meta-analyses.
The first one (13) includes 24 studies specifically centered
on computerized drill-and-practice training. This study
demonstrated that, compared with a control condition,
specific training obtains better results on attention, working
memory, and positive and depressive symptoms. Furthermore,
even if only marginally significant, small-to-moderate effects
were noticed for verbal fluency, processing speed, memory,
and verbal and visual learning. No evidence was found
sustaining improvement in general condition, reasoning
and problem solving, SC, and functional outcomes. The
second one (14) evaluates CR treatment effect on cognitive,
functional, and clinical outcomes in patients with SCZ
from 67 studies and found significant improvements with
small-to-moderate effect sizes in CR treatment on all of
the three outcome domains and suggests that cognitive
gains trigger improvement in both clinical symptoms and
psychosocial functioning.
Thus, some discrepancies across studies about SCZ (15) were
noticed regarding the improvement in community functioning
and SC following CR, while an improvement in cognition seems
to be commonly reported.
Therefore, in light of these considerations, the objective of
the present study was to evaluate, in a sample of outpatients
with SCZ, the effectiveness of a CR program (through the use
of the Cogpack software) in addition to standard therapy on
cognitive outcomes compared with a control active group (CAG)
and to evaluate if there is any impact on SC, metacognition,
symptomatology, and real-world functioning.
MATERIALS AND METHODS
Subjects
The present study was conducted at the Department of
Neuroscience “Rita Levi Montalcini,” University of Turin;
Department of Neuroscience and Mental Health, Psychiatry
Unit, AOU Città della Salute e della Scienza, Turin, Italy’ and the
Department of Mental Health, ASL TO3, Italy, between October
2017 and December 2019.
The trial was carried out in accordance with the Declaration
of Helsinki of 1995 (as revised in Edinburgh in 2000) and was
approved by the Local Ethical Committee on September 27, 2018
(Prot. N 00958893).
Inclusion Criteria
Patients, initially evaluated by a psychiatrist if they met the DSM-
5 criteria for the diagnosis of SCZ, were subsequently visited by
our research group. The patients examined were aged between 18
and 65 years. The study was conducted on a sample of outpatients
with diagnosis of SCZ in a stable phase of illness.
Exclusion Criteria
The exclusion criteria were the following: (a) co-presence of a
diagnosis of intellectual disability and learning disabilities; and
(b) hospitalization in psychiatric facilities in the 6 months prior
to evaluation and significant change of antipsychotic medications
during the previous 3 months (according to clinical judgment).
Participants were recruited through referrals from attending
psychiatrists or clinical staff at the psychiatric medical facilities
where the study was conducted.
Participants
Of the 153 patients with SCZ attending the two sites, only a
minority was approached for the study. Finally, 66 patients were
invited to participate. Details of factors contributing to reduction
of the number of potential participants are given in Figure 1.
Written informed consent was obtained from all subjects after
a complete description of the study.
All patients were submitted to standard care provided in
community mental health centers in Italy (pharmacological
treatment, clinical monitoring at least on a monthly basis, and
home care when required).
Interventions
All patients recruited in the trial were allocated to one of the two
interventions, CACR (Cogpack), and CAG. In this trial, patients
were considered completers if they attended at least 80% of the
planned sessions.
When a participant decided not to continue or stopped the
program session for at least 2 weeks or presented clinical relapse,
the participant was considered to have dropped out. Reasons for
discontinuation were registered.
Control Active Group
This condition was designed to control for non-specific
treatment effects. It specified an equal number of one-on-
one computer sessions with the same trainers who conducted
the CACR sessions, using the same schedule as the treatment
Frontiers in Psychiatry | www.frontiersin.org 2 July 2021 | Volume 12 | Article 649737
Montemagni et al. Cognitive Remediation in Schizophrenia
FIGURE 1 | Flow diagram of assessment for the eligibility in the two groups.
arm: 2-h biweekly sessions. It offered supportive trainer
interactions and matched experience with computers and varied
computer activities. Control activities were selected for game-
like properties and low cognitive demand. Participants in this
condition did not receive problem-solving training or guided
practice on the exercises used in the remediation condition.
Cognitive Remediation Group
The CACR group received 48 sessions computerized
rehabilitation using Cogpack software, performed twice a
week, for a total of 24 weeks of treatment, in addition to
standard therapy. CACR characteristics are described in another
paper (16).
Patients were evaluated using a semi-structured interview to
assess demographic and clinical features.
Psychiatric Assessment
All subjects were evaluated at baseline (T0), after 3 months (T1),
and after 6 months (T2).
Patients were assessed by two psychiatrists (ED and CR).
Neuropsychological tests were administered by a trained
psychologist (LC) who was unaware of the patients’ clinical
characteristics or the results of the psychiatric rating scales. The
battery was administered and scored according to the established
procedures for each test the day after the psychiatric assessment.
The raters were all masked with regard to the patient’s treatment
assignment, and patients were instructed not to reveal their
treatment to the investigators. The interviewing psychiatrists
were never members of the patients’ treating team.
Clinical Assessment
The Positive and Negative Syndrome Scale (PANSS) (17)
contains 30 items rated on 1 (absent) to 7 (extreme) scales. Three
symptom domains are included in the scale: positive symptoms
(seven items), negative symptoms (seven items), and general
psychopathology (16 items). Symptoms are typically rated for the
week immediately preceding the interview.
Depressive symptoms were evaluated using the Calgary
Depression Scale for Schizophrenia (CDSS) (18).
The Scale to assess the Unawareness of Mental Disorder
(SUMD) was used to assess illness insight (19). For the purpose
of the present research, data analysis was primarily focused on
current awareness and attribution of symptoms. All the scores
are located in a Likert-type scale from 1 (good insight) to 5 (no
insight). The insight of the patients was categorized as generally
“preserved” or “impaired” on a threshold mean score of ≤3.0.
Cognitive Assessment
The MATRICS Consensus Cognitive Battery (MCCB) (20)
consists of 10 measurement tools for recording the six
neurocognitive areas and the social–cognitive domain of
emotion perception. The six neurocognitive measures derive
from scores of 10 cognitive measures: processing speed
(Trail Making Test Part A; Brief Assessment of Cognition in
Schizophrenia: symbol coding; Category Fluency Test: animal
naming), attention/vigilance (Continuous Performance Test:
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identical pairs), working memory (Wechsler Memory Scale:
spatial span subset; Letter Number Span Test), verbal learning
(refers to immediate verbal memory, Hopkins Verbal Learning
Test (HVLT)-Revised, immediate recall), visual learning (refers
to immediate visual memory, Brief Visuospatial Memory Test-
Revised), reasoning, and problem solving (Neuropsychological
Assessment Battery (NAB), mazes subtest). The social–cognitive
domain is assessed by the Mayer–Salovey–Caruso Emotional
Intelligence Test (MSCEIT) (21), managing emotion section.
The Metacognition Assessment Scale (MAS) (22) was
developed to quantitatively assess synthetic aspects of
metacognition. MAS-A is a modification of the original
scale made in 2004 that contains four scales that pertain to
different foci of metacognitive acts: Self Reflectivity, or the
comprehension of one’s own mental states; Understanding of
others’minds, or the comprehension of other individuals’ mental
states; Decentration, which is the ability to see the world as
existing with others having independent motives; and Mastery,
which is the ability to use one’s mental states to implement
effective action strategies in order to accomplish cognitive tasks
or cope with psychological distress.
Real-World Functioning Assessment
The Specific Levels of Functioning Scale (SLOF) (23–25)
assesses the patient’s current functioning and behavior across
the following six domains: physical functioning, personal care
skills, interpersonal relationships, social acceptability, activities
of community living, and work skills. The rate of each questions
is included between 0 (the lowest level of functioning evaluated)
and 5 (the maximum level of functioning evaluated) on a 5-point
Likert scale, and the exact time frame that the survey attempts to
assess is unspecified.
Research Design and Data Analysis
Analyses were planned in two stages.
In stage 1, we performed chi-square tests for categorical
variables and the univariate analysis of variance (one-way
ANOVA) for continuous variables, to examine whether
the two groups differed in baseline demographic, clinical,
neuropsychological, and functional variables. p-Values <0.0083
(0.05/6) were considered significant.
In stage 2, pre-to-post treatment changes were analyzed
with repeated-measures ANOVA entering neurocognitive,
metacognitive, and functioning score subtests as the dependent
variables; time as the fixed factor (with the three levels T0, T1,
and T2); and treatment group as the independent variable. The
significance of F test for group × time interaction will indicate
if there are significant differences in outcomes between the
two groups.
Size effect was assessed with partial η2. Values ranging between
0.01 and 0.06 were considered as small effect, values ranging
between 0.07 and 0.14 were considered as medium effect, and
values higher than 0.14 were considered as large effect (26).
The researchers ensured that there were no significant outliers
in the related groups.
Statistical analyses were conducted using Statistical Package
for the Social Sciences, SPSS, version 25 for Windows (SPSS,
Chicago, IL, USA).
RESULTS
A total of 66 subjects were enrolled and provided consent to
participate in the study. Thirty-three of these patients were
allocated to CACR and 33 to the CAG. Ten patients dropped
out from the CACR group and eight from the CAG. Therefore,
the final sample included 23 patients in the CACR group and
25 subjects in the CAG. No statistical differences were found
between dropouts and completers in both groups (Tables 1, 2).
The flow diagram in Figure 1 shows dropout reasons in the
two groups.
Statistical analyses were performed on patients who
completed the sessions of treatment.
All the demographical, clinical, neuropsychological,
metacognitive, and functioning characteristics of the sample are
reported in Table 3.
No statistically differences in gender distribution, clinical,
and cognitive variables, and real-world functioning emerged
between the two groups, except for age, MAS self-reflectivity,
MAS decentration, as patients in the CACR group were younger,
and had a higher level of metacognition (self-reflectivity and
decentration) than those in the control group.
A significant improvement over trial duration (within-group
effect) was observed for both treatments in verbal learning, MAS
self-reflectivity, and MAS total score.
Moreover, patients in the CACR group demonstrated
significantly greater improvements over 6 months than the
control group (time × treatment interaction), with effect sizes
ranging from medium to high levels for MAS others’ mind
(h2 = 0.436), verbal learning (h2 = 0.321), SLOF interpersonal
relationship (h2 = 0.224), depressive symptoms (h2 = 0.215), SC
(h2 = 0.183), MAS mastery (η2 = 0.178), processing speed (η2
= 0.143), visual learning (h2 = 0.131), reasoning and problem
solving (h2 = 0.126), SLOF activities (h2 = 0.105), and awareness
of symptoms (h2 = 0.063).
Table 4 presents scores for the neuropsychological, clinical,
and functional outcomes at baseline and post-intervention.
DISCUSSION
Our study was aimed to assess the effectiveness of CACR vs.
a CAG on specific cognitive, clinical, and functional domains
in a sample of outpatients with SCZ. The CACR group was
compared with an active experimental condition centered on
non-specific elements of the remediation training, such as
supportive therapist interactions and exposure to interesting
computer activities. Outcomes were evaluated at three levels:
proximally, on the remediation training exercises; intermediately,
on neuropsychological measures not involved in the training;
and more distally, on proxy measures of everyday functioning.
Both groups were well-matched at baseline evaluation on
demographic (except for age) and clinical confounding variables
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TABLE 1 | Differences between drop-outs and CAG group completers.
Variables Condition SD F/X2 p-value
CAG Drop CAG Drop
Age 42.72 41.75 8.473 4.432 0.095 0.760
Gender (male)* 10 2 0.589 0.443
Employment (unemployed)* 8 1 1.162 0.281
Schooling (years) 11.08 12.63 3.82 2.875 1.100 0.302
Age of onset 25.68 21.13 7.5 3.441 2.729 0.109
PANSS-P 11.83 12.63 2.98 1.085 1.056 0.312
PANSS-N 22.0 24.13 7.12 1.856 0.602 0.444
PANSS-G 36.08 39.75 9.98 2.455 0.928 0.343
PANSS total 72.96 77.25 17.95 4.705 0.385 0.539
MAS self-reflectivity 4.52 6.13 2.35 0.459 3.346 0.081
MAS others’ mind 3.76 3.13 2.03 0.479 0.680 0.416
MAS decentration 0.4 1.00 0.95 0.378 2.255 0.143
MAS mastery 2.92 2.88 2.71 0.125 0.030 0.863
MAS total 11.6 11.13 6.99 1.575 0.032 0.859
CDSS 1.8 1.75 2.04 0.526 0.004 0.950
Verbal memory 33.36 36.00 8.64 2.260 2.800 0.104
Reasoning/probl. solving 32.28 33.75 4.71 3.614 0.32 0.575
Visual memory 35.92 34.75 14.07 5.130 0.041 0.840
Attention/vigilance 28.36 27.63 9.03 1.456 0.049 0.827
SC 27.4 30.25 10.74 3.858 0.424 0.520
Processing speed 24.48 26.00 9.99 2.87 0.165 0.688
Working memory 29.24 36.00 10.76 2.260 2.800 0.104
SLOF physic func 24.6 24.63 1.04 0.183 0.004 0.949
SLOF personal care 32.76 34.25 2.78 0.126 2.085 0.159
SLOF Int. relation 22.12 20.13 4.3 1.716 1.231 0.276
SLOF social accept 31.44 32.50 4.12 0.732 0.482 0.493
SLOF activities 47.76 43.25 5.67 2.448 3.449 0.073
SLOF work skills 19.64 18.75 5.37 2.651 0.137 0.714
SLOF total 179.12 175.75 17.36 6.475 2.926 0.097
SUMD awareness 3.22 3,016 0.65 0.269 0.559 0.460
SUMD attribution 3.35 3.740 0.78 0.329 1.391 0.247
PANSS-P, Positive and Negative Syndrome Scale, positive symptoms; PANSS-N, Positive and Negative Syndrome Scale, negative symptoms; PANSS-G, Positive and Negative
Syndrome Scale, general, psychopathology; PANSS Total, Positive and Negative Syndrome Scale, total; MAS Self-reflectivity, Metacognition Assessment Scale, self-reflectivity; MAS
Others’ mind, Metacognition Assessment Scale, understanding of others’ mind; MAS Decentration, Metacognition Assessment Scale, decentration; MAS Mastery, Metacognition
Assessment Scale, mastery; MAS Total, Metacognition Assessment Scale, total; CDSS, Calgary Depression Symptoms Scale; Verbal memory, MCCB, verbal memory; Reasoning/Probl.
solving, MCCB, reasoning and problem solving; Visual memory, MCCB, visual memory; Attention/Vigilance, MCCB, attention/vigilance; SC, MCCB, social cognition; Processing speed,
MCCB, processing speed; Working memory, MCCB, working memory; SLOF Physical func, Specific Levels of Functioning Scale, physical functioning; SLOF Personal care, Specific
Levels of Functioning Scale, personal care skills; SLOF Int. relation, Specific Levels of Functioning Scale, interpersonal relationships; SLOF Social accept, Specific Levels of Functioning
Scale, social acceptability; SLOF Activities, Specific Levels of Functioning Scale, activities of community living; SLOFWork skills, Specific Levels of Functioning Scale, work skills; SLOF Int.
relation, Specific Levels of Functioning Scale, total; SUMD Awareness, Scale to Assess Unawareness in Mental Disorder, awareness; SUMD Attribution, Scale to Assess Unawareness
in Mental Disorder, attribution; CAG, control active group. *Dichotomous variable.
(i.e., metacognitive abilities) that might negatively impact
outcome measures and might create a bias in study results.
Furthermore, as indicated in a recent and relevant study,
age does not appear to represent a significant moderator of
effect (27).
There are several key observations from the study.
First, results showed a satisfactory adherence rate, with
almost 70% of the participants completing the entire course
of the protocol and adhering to over 80% of the prescribed
sessions and outcome measures, suggesting that subjects did
not seem to find the time commitment, the assessments,
or the training burdensome. These completion rates are
comparable with some studies (15, 28–30) and in contrast
with other ones conducted so far (31), showing a higher
attrition rate. Nevertheless, the present study adopted several
measures to sustain adherence, mostly by strengthening the
relationship with the therapist that has been shown to have
a fundamental role in ensuring participants’ completion of
the training modules (32) and providing social cues to
improve patients’ self-esteem and motivation, supporting the
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TABLE 2 | Differences between drop-outs and CACR group completers.
Variables Condition SD F/X2 p-value
Drop CACR Drop CACR
Age 33.20 31.24 3.155 9.34 0.000 0.985
Gender (male)* 5 18 2.636 0.104
Employment (unemployed)* 5 6 1.793 0.181
Schooling (years) 11.40 12.88 4.377 2.49 0.858 0.356
Age of onset 24.60 23.32 1.857 4.81 0.254 0.618
PANSS-P 14.50 15.24 2.729 6.93 0.457 0.504
PANSS-N 23.60 23.87 2.554 5.75 0.054 0.818
PANSS-G 36.70 37.39 3.927 9.27 0.021 0.887
PANSS total 73.90 73.53 7.287 15.54 0.026 0.874
MAS self-reflectivity 5.80 6.7 0.573 2.08 0.935 0.341
MAS others’ mind 3.00 3.78 0.615 1.98 0.459 0.503
MAS decentration 0.30 1.26 0.300 1.25 3.952 0.056
MAS mastery 1.50 3.39 0.872 2.78 1.987 0.179
MAS total 15.90 15.13 1.622 6.59 0.798 0.378
CDSS 1.10 2.78 0.379 3.37 3.653 0.065
Verbal memory 33.20 37.35 1.806 9 1.128 0.297
Reasoning/probl. solving 31.50 34.43 1.293 10 0.155 0.697
Visual memory 35.40 37.22 2.754 15.78 0.153 0.698
Attention/vigilance 27.60 34.83 9.03 2.980 4.094 0.053
SC 34.20 33.81 3.623 12.53 0.158 0.676
Processing speed 22.50 26.91 2.786 7.72 0.529 0.473
Working memory 30.90 33.3 3.659 8.57 0.057 0.812
SLOF physic func 24.70 24.63 0.153 0.87 2.301 0.140
SLOF personal care 32.70 32.65 0.978 3.3 0.271 0.607
SLOF Int. relation 20.30 20.96 1.484 5.79 0.005 0.945
SLOF social accept. 33.136 34.65 0.194 0.78 1.693 0.203
SLOF activities 45.30 44.7 1.898 6.87 1.061 0.807
SLOF work skills 18.80 19.74 1.526 6.37 0.044 0.836
SLOF total 173.50 177.7 4.679 19.25 0.223 0.640
SUMD awareness 3.136 2.74 0.194 0.93 3.847 0.059
SUMD attribution 3.332 3.03 0.268 1.13 1.377 0.250
PANSS-P, Positive and Negative Syndrome Scale, positive symptoms; PANSS-N, Positive and Negative Syndrome Scale, negative symptoms; PANSS-G, Positive and Negative
Syndrome Scale, general, psychopathology; PANSS Total, Positive and Negative Syndrome Scale, total; MAS Self-reflectivity, Metacognition Assessment Scale, self-reflectivity; MAS
Others’ mind, Metacognition Assessment Scale, understanding of others’ mind; MAS Decentration, Metacognition Assessment Scale, decentration; MAS Mastery, Metacognition
Assessment Scale, mastery; MAS Total, Metacognition Assessment Scale, total; CDSS, Calgary Depression Symptoms Scale; Verbal memory, MCCB, verbal memory; Reasoning/Probl.
solving, MCCB, reasoning and problem solving; Visual memory, MCCB, visual memory; Attention/Vigilance, MCCB, attention/vigilance; SC, MCCB, social cognition; Processing speed,
MCCB, processing speed; Working memory, MCCB, working memory; SLOF Physical func, Specific Levels of Functioning Scale, physical functioning; SLOF Personal care, Specific
Levels of Functioning Scale, personal care skills; SLOF Int. relation, Specific Levels of Functioning Scale, interpersonal relationships; SLOF Social accept, Specific Levels of Functioning
Scale, social acceptability; SLOF Activities, Specific Levels of Functioning Scale, activities of community living; SLOFWork skills, Specific Levels of Functioning Scale, work skills; SLOF Int.
relation, Specific Levels of Functioning Scale, total; SUMD Awareness, Scale to Assess Unawareness in Mental Disorder, awareness; SUMD Attribution, Scale to Assess Unawareness
in Mental Disorder, attribution; CAG, control active group; CACR, computer-assisted cognitive remediation. *Dichotomous variable.
use of strategies, motivation, or reinforcement and helping
to develop metacognition, which is thought to be a key
component for improving transfer from cognitive change to
functional development (33, 34). Indeed, supportive, adaptive,
and instructive trainers are thought to be a key ingredient
of CACR programs and ultimately what makes them a
therapeutic tool rather than a common “brain training,”
being instrumental in achieving better training outcomes in
CR (34, 35).
Second, while verbal learning and metacognitive sub-
functions (understanding one’s own mind and MAS total score)
improved over assessment occasions, a significant time × group
interaction was evident, suggesting that patients undergoing
CACR intervention improved in domains related to specific
cognitive domains (reasoning and problem solving, visual
learning, verbal learning, and processing speed), understanding
others’ mind, mastery, SC, depressive symptoms, awareness of
symptoms, and real-world functioning domains (community
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TABLE 3 | Demographical, clinical, neuropsychological, metacognitive and functioning characteristics of the sample.
Variables Condition SD F/X2 p-value
CAG CACR CAG CACR
Age 42.72 31.24 8.47 9.34 25.1 <0.001
Gender (male)* 10 18 1.79 0.181
Employment (unemployed)* 8 6 0.20 0.653
Schooling (years) 11.08 12.88 3.82 2.49 5.37 0.02
Age of onset 25.68 23.32 7.5 4.81 2.44 0.12
PANSS-P 11.83 15.24 2.98 6.93 2.07 0.16
PANSS-N 22.0 23.87 7.12 5.75 0.4 0.53
PANSS-G 36.08 37.39 9.98 9.27 0.33 0.57
PANSS total 72.96 73.53 17.95 15.54 0.02 0.9
MAS self-reflectivity 4.52 6.7 2.35 2.08 15.02 <0.001
MAS others’ mind 3.76 3.78 2.03 1.98 0.21 0.65
MAS decentration 0.4 1.26 0.95 1.25 11.1 0.001
MAS mastery 2.92 3.39 2.71 2.78 0.18 0.67
MAS total 11.6 15.13 6.99 6.59 5.03 0.03
CDSS 1.8 2.78 2.04 3.37 3.69 0.059
Verbal memory 33.36 37.35 8.64 9 2.99 0.09
Reasoning/Probl. solving 32.28 34.43 4.71 10 2.15 0.15
Visual memory 35.92 37.22 14.07 15.78 1.18 0.28
Attention/vigilance 28.36 34.83 9.03 10.57 5.41 0.02
SC 27.4 33.81 10.74 12.53 7.85 0.01
Processing speed 24.48 26.91 9.99 7.72 0.96 0.33
Working memory 29.24 33.3 10.76 8.57 3.75 0.06
SLOF physic func 24.6 24.63 1.04 0.87 0.01 0.92
SLOF personal care 32.76 32.65 2.78 3.3 0.04 0.85
SLOF Int. relation 22.12 20.96 4.3 5.79 1.0 0.32
SLOF social accept 31.44 34.65 4.12 0.78 8.53 0.01
SLOF activities 47.76 44.7 5.67 6.87 2.1 0.15
SLOF work skills 19.64 19.74 5.37 6.37 0.19 0.67
SLOF total 179.12 177.7 17.36 19.25 0.14 0.71
SUMD awareness 3.22 2.74 0.65 0.93 10.839 0.002
SUMD attribution 3.35 3.03 0.78 1.13 3.328 0.073
PANSS-P, Positive and Negative Syndrome Scale, positive symptoms; PANSS-N, Positive and Negative Syndrome Scale, negative symptoms; PANSS-G, Positive and Negative
Syndrome Scale, general, psychopathology; PANSS Total, Positive and Negative Syndrome Scale, total; MAS Self-reflectivity, Metacognition Assessment Scale, self-reflectivity; MAS
Others’ mind, Metacognition Assessment Scale, understanding of others’ mind; MAS Decentration, Metacognition Assessment Scale, decentration; MAS Mastery, Metacognition
Assessment Scale, mastery; MAS Total, Metacognition Assessment Scale, total; CDSS, Calgary Depression Symptoms Scale; Verbal memory, MCCB, verbal memory; Reasoning/Probl.
solving, MCCB, reasoning and problem solving; Visual memory, MCCB, visual memory; Attention/Vigilance, MCCB, attention/vigilance; SC, MCCB, social cognition; Processing speed,
MCCB, processing speed; Working memory, MCCB, working memory; SLOF Physical func, Specific Levels of Functioning Scale, physical functioning; SLOF Personal care, Specific
Levels of Functioning Scale, personal care skills; SLOF Int. relation, Specific Levels of Functioning Scale, interpersonal relationships; SLOF Social accept, Specific Levels of Functioning
Scale, social acceptability; SLOF Activities, Specific Levels of Functioning Scale, activities of community living; SLOFWork skills, Specific Levels of Functioning Scale, work skills; SLOF Int.
relation, Specific Levels of Functioning Scale, total; SUMD Awareness, Scale to Assess Unawareness in Mental Disorder, awareness; SUMD Attribution, Scale to Assess Unawareness
in Mental Disorder, attribution; CAG, control active group; CACR, computer-assisted cognitive remediation. *Dichotomous variable.
activities and interpersonal relationships) more significantly than
did patients undergoing control active intervention.
Third, overall, the most noticeable differential improvement
between the two groups were detected in two metacognitive
sub-functions (understanding others’ mind and mastery), in two
cognitive domains (verbal learning and processing speed), in
SLOF interpersonal relationship, in depressive symptomatology,
and in SC, with effect sizes ranging from medium to high levels
(see Table 1).
The positive findings regarding the amelioration of verbal and
visual learning and reasoning and problem solving reported in
the present study are consistent with the results of prior studies
(13). The advantage of CR for verbal and visual learning support
the possibility that at least some additional neurocognitive benefit
may derive from an accurate titration of task difficulty of
cognitive exercises to guarantee appropriate cognitive challenge,
the rapid repetition of exacting exercises, and the frequency
of reinforcement associated with achievement of intermediate
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TABLE 4 | Scores for the neuropsychological, clinical, and functional outcomes at baseline and post-intervention.
Variables T CAG (n = 25) CACR (n = 23) Source F p-value η2 partial
M ± SD M ± SD
PANSS-P T0 11.83 ± , 2.98 15.24 ±6.92 Group 1.639 0.209 0.047
T1 11.26 ± 3.57 12.00 ±6.92 Time 4.012 0.053 0.108
T2 12.13 ± 4.61 12.00 ±3.92 G * T 0.602 0.443 0.018
PANSS-N T0 22 ± 7.12 23.87 ±5.75 Group 0.009 0.252 0.040
T1 21.52 ± 6.48 20.78 ±4.5 Time 0.688 0.413 0.020
T2 21.52 ± 6.48 19.61 ±4.53 G * T 2.817 0.103 0.079
PANSS-G T0 36.08 ± 9.98 37.39 ±9.27 Group 0.779 0.384 0.023
T1 33.88 ± 11.96 32.70 ±7.23 Time 0.803 0.377 0.024
T2 33.88 ± 11.96 31.43 ±7.14 G * T 1.007 0.323 0.030
MAS
self-reflectivity
T0 4.52 ± 2.35 6.7 ±2.08 Group 20.839 0.000 0.387
T1 4.24 ± 2.11 7.0 ±1.83 Time 6.641 0.002 0.161
T2 4.64 ± 2.1 7.35 ±1.27 G * T 2.212 0.146 0.063
MAS others’ mind T0 3.76 ± 2.03 3.78 ±1.98 Group 4.421 0.043 0.118
T1 3.8 ± 1.76 4.09 ±1.89 Time 3.947 0.055 0.107
T2 3.76 ± 1.83 4.83 ±1.7 G * T 25.467 0.000 0.436
MAS decentrat T0 0.4 ± 0.96 1.26 ±1.25 Group 1.024 0.000 0.487
T1 0.52 ± 0.87 1.35 ±1.19 Time 1.053 0.312 0.031
T2 0.68 ± 1.14 1.61 ±1.08 G * T 0.009 0.926 0.000
MAS mastery T0 2.92 ± 2.71 3.39 ±2.78 Group 0.095 0.760 0.003
T1 2.56 ± 1.94 3.35 ±2.41 Time 1.788 0.190 0.051
T2 2.88 ± 2.28 4.39 ±1.99 G * T 7.148 0.012 0.178
MAS total T0 11.6 ± 6.99 15.13 ±6.59 Group 8.79 0.005 0.16
T1 11.12 ± 5.55 15.83 ±5.58 Time 5.89 0.004 0.114
T2 11.96 ± 6.64 18.22 ±4.64 G * T 2.96 0.057 0.06
CDSS T0 1.8 ± 2.04 2.78 ±3.37 Group 0.505 0.482 0.015
T1 3.68 ± 3.73 2.22 ±2.81 Time 0.332 0.568 0.010
T2 3.68 ± 3.73 2.04 ±3.39 G * T 9.035 0.005 0.215
Verb. learn T0 33.36 ± 8.64 37.35 ±9.00 Group 5.071 0.031 1.33
T1 31.84 ± 6.01 42.74 ±10.81 Time 4.321 0.045 0.116
T2 31.84 ± 6.01 45.83 ±10.44 G * T 15.613 0.000 0.321
Reas/prob solving T0 32.28 ± 4.71 34.43 ±10 Group 17.056 0.000 0.341
T1 30.08 ± 3.9 36.61 ±8.59 Time 0.154 0.697 0.005
T2 30.08 ± 3.09 39.35 ±7.99 G * T 15.406 0.000 0.318
Visual learn T0 35.92 ± 14.07 37.22 ±15.68 Group 5.236 0.029 0.137
T1 33.24 ± 12.19 45.09 ±15.35 Time 0.095 0.760 0.003
T2 33.24 ± 12.19 49.78 ±13.58 G * T 4.208 0.048 0.113
Att/Vig T0 28.36 ± 9.03 34.83 ±10.57 Group 7.230 0.011 0.180
T1 27.4 ± 7.27 36.43 ±10.02 Time 1.799 0.189 0.052
T2 27.4 ± 7.27 36.43 ±12.06 G * T 0.504 0.483 0.015
SC T0 27.4 ± 10.74 33.81 ±12.53 Group 9.385 0.005 0.238
T1 25.52 ± 5.9 38.67 ±12.45 Time 3.333 0.78 0.100
T2 25.52 ± 5.9 40.76 ±12.48 G * T 6.710 0.015 0.183
Process speed T0 24.48 ± 9.99 26.91 ±7.72 Group 3.147 0.085 0.087
T1 24.68 ± 7.11 32.48 ±9.25 Time 0.439 0.512 0.013
T2 24.68 ± 7.11 33 ±11.12 G * T 5.491 0.025 0.143
Working memory T0 29.24 ± 10.76 33.3 ±8.57 Group 0.279 0.601 0.008
T1 29.64 ± 11.16 37.04 ±8.71 Time 1.261 0.270 0.037
T2 29.64 ± 11.16 36.83 ±10.7 G * T 0.863 0.360 0.025
SLOF total T0 179.12 ± 17.36 177.7 ±19.25 Group 0.247 0.622 0.007
(Continued)
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TABLE 4 | Continued
Variables T CAG (n = 25) CACR (n = 23) Source F p-value η2 partial
M ± SD M ± SD
T1 175.84 ± 16.78 184.91 ±12.81 Time 0.076 0.784 0.002
T2 175.84 ± 16.77 184.43 ±14.83 G * T 3.220 0.082 0.089
SLOF Pers. care T0 32.76 ± 2.77 32.65 ±3.3 Group 0.071 0.792 0.002
T1 32.24 ± 2.49 33.35 ±2.82 Time 0.812 0.374 0.024
T2 32.24 ± 2.49 33.26 ±2.03 G * T 0.484 0.492 0.014
SLOF Int. relation T0 22.12 ± 4.3 20.96 ±5.79 Group 1.146 0.292 0.34
T1 20.8 ± 5.31 23.91 ±4.33 Time 1.556 0.221 0.045
T2 20.8 ± 5.31 24.04 ±5.41 G * T 9.530 0.004 0.224
SLOF social acc T0 31.44 ± 4.12 34.65 ±0.78 Group 7.686 0.009 0.189
T1 32.8 ± 3.86 34.83 ±0.65 Time 0.306 0.584 0.009
T2 32.8 ± 3.86 34.83 ±0.39 G * T 0.709 0.406 0.021
SLOF activities T0 47.76 ± 5.67 44.7 ±6.87 Group 0.097 0.758 0.003
T1 44.48 ± 6.97 46.13 ±5.24 Time 0.006 0.938 0.000
T2 44.98 ± 6.97 46.17 ±5.93 G * T 3.885 0.049 0.105
SLOF work skills T0 19.64 ± 5.37 19.74 ±6.37 Group 0.071 0.792 0.002
T1 20.32 ± 4.89 21.48 ±5.6 Time 0.041 0.841 0.001
T2 20.32 ± 4.89 21.61 ±5.58 G * T 0.035 0.853 0.001
SUMD aw T0 3.22 ± 0.65 2.74 ±0.93 Group 3.654 0.065 0.100
T1 3.22 ± 0.65 2.54 ±0.72 Time 0.378 0.543 0.011
T2 3.34 ± 0.66 2.49 ±0.71 G * T 3.791 0.041 0.073
SUMD at T0 3.35 ± 0.78 3.03 ±1.13 Group 0.492 0.488 0.015
T1 3.35 ± 0.78 2.97 ±0.86 Time 0.113 0.739 0.003
T2 3.43 ± 0.74 2.79 ±0.88 G * T 0.005 0.944 0.000
PANSS-P, Positive and Negative Syndrome Scale, positive symptoms; PANSS-N, Positive and Negative Syndrome Scale, negative symptoms; PANSS-G, Positive and Negative
Syndrome Scale, general, psychopathology; MAS Self-reflectivity, Metacognition Assessment Scale, self-reflectivity; MAS others’ mind, Metacognition Assessment Scale, understanding
of others’ mind; MASDecentrat, Metacognition Assessment Scale, decentration; MASMastery, Metacognition Assessment Scale, mastery; MAS Total, Metacognition Assessment Scale,
total; CDSS, Calgary Depression Symptom Scale; Verb. learn, MCCB, verbal learning; Reas/Prob solving, MCCB, reasoning and problem solving; Visual learn, MCCB, visual learning;
Att/Vig, MCCB, attention/vigilance; SC, MCCB, social cognition; Process speed, MCCB, processing speed; Working memory, MCCB, working memory; SLOF Total, Specific Levels of
Functioning Scale, total; SLOF Pers. care, Specific Levels of Functioning Scale, personal care skills; SLOF Int relation, Specific Levels of Functioning Scale, interpersonal relationships;
SLOF Social acc, Specific Levels of Functioning Scale, social acceptability; SLOF Activities, Specific Levels of Functioning Scale, activities of community living; SLOF Work skill, Specific
Levels of Functioning Scale, work skills; SUMD aw, Scale to Assess Unawareness in Mental Disorder, awareness; SUMD at, Scale to Assess Unawareness in Mental Disorder, attribution;
CAG, control active group; CACR, computer-assisted cognitive remediation.
and overall task goals characteristic of this condition. The
hierarchical nature of the training program, starting with training
in elementary attention skills and then gradually shifting to
considerably more complex episodic and verbal memory tasks,
might play a role in the advantage of this condition (36).
Thus, it is a paradox that there is no finding supporting
an advantage of CACR on working memory (a skill related
to holding information in mind and manipulating that
information), while there is extensive evidence of CACR
advantage in reasoning/executive-function and problem-solving
domains. This result would not be expected because several
studies have shown a close link between elementary working-
memory functions and higher-level reasoning and problem-
solving skills (37). Our results could be explained by the
teaching strategies used by the therapist during and after CACR
training sessions. Indeed, the one-to-one interaction with a
therapist who can explicitly promote “bridging” strategies, as
well as provide non-specific support and motivational coaching,
represents important elements of the CACR therapy.
As for SC, we found a significant effect for this domain
in the CACR group compared with the CAG. SC is the set
of mental functions that allow individuals to interact with
each other, i.e., the ability to understand, predict, and respond
appropriately to the thoughts, feelings, and behavior of others
in different and often unfamiliar social contexts (38, 39). The
integrity of basic neuropsychological functions constitutes an
essential prerequisite for the development of an adequate SC.
Almost all published CACR studies agree that when coupled with
rehabilitative programs focused on emotional intelligence, the
benefits on recognition of emotions and the ability to interpret
the feelings and behavior of others are improved (40, 41).
However, the three studies included in the meta-analysis of
Prikken et al. (13) did not detect a connection between CACR
treatment and an improvement in emotional intelligence.
Alongside the improvement in neurocognitive functioning
and SC obtained in the CACR group, we found an improvement
in the metacognition (understanding others’ mind and mastery)
and insight (awareness of symptoms).
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“Metacognition” identifies the main skills currently used
to understand mental state and to properly attribute it to
oneself or others. These skills include the ability to decipher
the emotion expressions, to reason about mental states, and
to use the obtained information to decide and solve problems
and/or interpersonal conflicts. Finally, all these abilities also allow
everyone to manage the subjective sufferance (42–44). It has been
described as the memory processes that are related to the insights
people have about their own and others’ cognitive processes.
In order to develop an appropriate insight, metacognitive
processes are fundamental because they allow individuals to
notice changes in mental state over time and to produce plausible
explanations for them, becoming more aware of their psychotic
illness (45). Unfortunately, even if it is known that insight and
metacognition are two integrative cognitive abilities, the exact
neural and cognitive processes that support them are still unclear.
However, the great impairments in neurocognition (verbal,
working, and visual memory; executive function; and overall
intelligence) showed by patients with SCZ may be related to the
severe deficits in metacognition (45–48). This impairment may
lead to a lower ability to form complex mental representations of
themselves and others (45, 46). In fact, SCZ patients with poor
verbal memory might show more difficulties in remembering
and integrating life experiences, even losing sense of previous
experiences, with consequences in understanding the context
complexity and their proper and others role on it (49).
Thus, the observed improvements in metacognitive skills
and awareness of symptoms may be related to changes in
neurocognitive functioning due to CACR in our study. Another
possible explanation may be that the CACR group provided
treatments in which patients’ ability to reflect and to think about
themselves was fostered to a greater extent than during a control
active task. Indeed, all CACR sessions were facilitated by trained
therapists who actively interacted with all participants to support
their progression with the exercises, did troubleshooting, and
spent time with participants on difficult exercises.
Moreover, participants showed significant improvements in
two real-world functioning domains (interpersonal relationships
and community activities) from baseline to 6-month follow-up
with large effect sizes. The impact of CACR on psychosocial
functioning is still controversial. A meta-analysis of Prikken et al.
(13) found small-to-moderate but only marginally significant
effects on functional outcomes. This finding is in contrast with
other studies, also including strategy training, which showed
larger and significant effects (9–11). It is plausible that CACR
training alone might not be enough to improve daily functioning.
Moreover, it has been observed that 6months of treatment period
might be too short to evaluate more differences in functioning
between the two groups; probably, some changes in real-world
functioning need a longer time to become evident, such as 1 year
or more.
A plausible explanation of our results may be found on the fact
that beneficial effects on verbal and visual memory may mediate
the effect of CACR on social functioning; i.e., verbal memory
has been considered to be associated with social competence
(50) and daily functioning (51, 52); better visual–spatial memory
after CACR may favor better skills in recognizing visual cues
in social interactions and hence favor better social response
and adaptation after CACR (53). Second, on the other hand,
it appears that learning strategies could be a prerequisite for
generalization of CACR treatment effects, explaining the reason
why improvement in neurocognition does not automatically
translate into improvement in social functioning (54, 55). Indeed,
it was demonstrated that CACR can better influence functional
outcomes when we give patients the opportunity to train
cognitive skills in a context of a social learning environment
through transferring skills from laboratory to real world (10, 55–
57). According to this knowledge, our protocol study included a
10-min discussion with the therapist at the end of each CACR
session in order to help in transferring learned abilities to the real
world. Moreover, the differences in literature might depend on
the different scales used to evaluate patients.
This study presents some limitations. First, the sample size is
relatively small. Second, only patients in stable phase of disease
were included, limiting generalization of the results toward
the whole SCZ population. Third, there was no independent
randomization. This clearly reduces methodological quality,
although, current empirical evidence seems to indicate that non-
randomized allocation does not influence effect sizes of cognitive
training interventions (9). Fourth, the choice of the control
intervention might represent another factor that theoretically has
the potential to influence whether CACR is found to be effective
or not (9). The CAG we employed engaged cognitive functions,
not of a drill-and-practice type. A task with minimal demands
on executive function was used, and while it does require
memory skills, in this case, it involved procedural memory
that is universally considered to be dissociable from episodic
memory and trained in CACR (58). Furthermore, our control
intervention therapeutic is unlikely to be considered because
we found significant differences at the end of the treatment
between the CACR and the CAG on some neuropsychological
measures. Fifth, a factor that might have impacted the results
of our study is that it was conducted in open units, where
patients had the opportunity to go out to the community; this
could have introduced uncontrolled variable, i.e., time spent in
the community. Sixth, it could be argued that our study lacks
enough power to detect differences between CACR and control
group. It is a common issue in CACR trials, because detection of
small effects requires large samples, and the recruitment of large
group of patients is a great challenge, especially when trials are
conducted in a single unit (59). Lastly, this study has not done a
follow-up evaluation; for this reason, it lacks information about
the duration of the outcomes.
Some strengths of this study deserve to be noticed,
such as the well-matched baseline clinical, demographic, and
cognitive characteristics of the two groups; the accurate
assessment of cognitive functions, performed through the
MCCB, and of real-world functioning, evaluated through
the SLOF that is considered as the best scale to estimate
psychosocial functioning of SCZ patients among those included
in the VALERO program. Moreover, diagnoses were based on
structured clinical interviews, and all patients were evaluated
by trained raters. A further strength of this study is that the
control group had the same number of hours of computer
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exposure as the treatment group. Lastly, another advantage
is that there was no changing in pharmacological treatment
during the study, allowing to specifically explain the effect
of interventions.
In conclusion, if confirmed, our data point out the
strength of CACR in implementing cognitive skills, SC, insight,
metacognitive skills, and functioning in daily life in patients with
SCZ. These are encouraging findings in support of the possible
integration of CACR in rehabilitation practice in the Italian
mental health services.
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